FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098751189> ?p ?o ?g. }

• W2098751189 endingPage "1295" @default.
• W2098751189 startingPage "1290" @default.
• W2098751189 abstract "Rationale: Lipoprotein apheresis (LA) reduces low-density lipoprotein (LDL) levels in patients with severe familial hypercholesterolemia (FH). We have recently reported that >30% of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) is bound to LDL, thus we predicted that LA would also reduce plasma PCSK9 levels by removing LDL. Objective: Pre- and post-apheresis plasma from 6 patients with familial hypercholesterolemia on 3 consecutive treatment cycles was used to determine changes in PCSK9 levels. Methods and Results: LA drastically reduced plasma LDL (by 77±4%). Concomitantly, PCSK9 levels fell by 52±5%, strongly correlating with the LDL drop ( P =0.0322; r 2 =0.26), but not with decreases in triglyceride (49±13%) or high-density lipoprotein levels (18±2%). Levels of albumin, creatinine, and CK-MB did not show significant changes after LA. Similar to LDL, PCSK9 levels returned to pretreatment values between cycles (2-week intervals). Fractionation of pre- and post-apheresis plasma showed that 81±11% of LDL-bound PCSK9 and 48±14% of apolipoprotein B–free PCSK9 were removed. Separation of whole plasma, purified LDL, or the apolipoprotein B–free fraction through a scaled-down, experimental dextran sulfate cellulose beads column produced similar results. Conclusions: Our results show, for the first time, that modulation of LDL levels by LA directly affects plasma PCSK9 levels, and suggest that PCSK9 reduction is an additional benefit of LA. Because the loss of PCSK9 could contribute to the LDL-lowering effect of LA, then (1) anti-PCSK9 therapies may reduce frequency of LA in patients currently approved for therapy, and (2) LA and anti-PCSK9 therapies may be used synergistically to reduce treatment burden." @default.
• W2098751189 created "2016-06-24" @default.
• W2098751189 creator A5067797353 @default.
• W2098751189 creator A5068826784 @default.
• W2098751189 creator A5071143988 @default.
• W2098751189 creator A5089000198 @default.
• W2098751189 date "2013-12-06" @default.
• W2098751189 modified "2023-10-12" @default.
• W2098751189 title "Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis" @default.
• W2098751189 cites W162053157 @default.
• W2098751189 cites W1970743796 @default.
• W2098751189 cites W1978080134 @default.
• W2098751189 cites W1989074039 @default.
• W2098751189 cites W2004032902 @default.
• W2098751189 cites W2013982259 @default.
• W2098751189 cites W2019559527 @default.
• W2098751189 cites W2026136832 @default.
• W2098751189 cites W2029459374 @default.
• W2098751189 cites W2047908832 @default.
• W2098751189 cites W2060302153 @default.
• W2098751189 cites W2077470670 @default.
• W2098751189 cites W2088794717 @default.
• W2098751189 cites W2091233171 @default.
• W2098751189 cites W2103647780 @default.
• W2098751189 cites W2107513378 @default.
• W2098751189 cites W2108956796 @default.
• W2098751189 cites W2112345742 @default.
• W2098751189 cites W2112801951 @default.
• W2098751189 cites W2114918865 @default.
• W2098751189 cites W2118033940 @default.
• W2098751189 cites W2122864632 @default.
• W2098751189 cites W2128030263 @default.
• W2098751189 cites W2135759335 @default.
• W2098751189 cites W2146769790 @default.
• W2098751189 cites W2153463741 @default.
• W2098751189 cites W2162679776 @default.
• W2098751189 cites W2314509776 @default.
• W2098751189 cites W4249898731 @default.
• W2098751189 doi "https://doi.org/10.1161/circresaha.113.302655" @default.
• W2098751189 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3939022" @default.
• W2098751189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24122718" @default.
• W2098751189 hasPublicationYear "2013" @default.
• W2098751189 type Work @default.
• W2098751189 sameAs 2098751189 @default.
• W2098751189 citedByCount "74" @default.
• W2098751189 countsByYear W20987511892014 @default.
• W2098751189 countsByYear W20987511892015 @default.
• W2098751189 countsByYear W20987511892016 @default.
• W2098751189 countsByYear W20987511892017 @default.
• W2098751189 countsByYear W20987511892018 @default.
• W2098751189 countsByYear W20987511892019 @default.
• W2098751189 countsByYear W20987511892020 @default.
• W2098751189 countsByYear W20987511892021 @default.
• W2098751189 countsByYear W20987511892022 @default.
• W2098751189 countsByYear W20987511892023 @default.
• W2098751189 crossrefType "journal-article" @default.
• W2098751189 hasAuthorship W2098751189A5067797353 @default.
• W2098751189 hasAuthorship W2098751189A5068826784 @default.
• W2098751189 hasAuthorship W2098751189A5071143988 @default.
• W2098751189 hasAuthorship W2098751189A5089000198 @default.
• W2098751189 hasBestOaLocation W20987511891 @default.
• W2098751189 hasConcept C126322002 @default.
• W2098751189 hasConcept C134018914 @default.
• W2098751189 hasConcept C185592680 @default.
• W2098751189 hasConcept C2776104379 @default.
• W2098751189 hasConcept C2778163477 @default.
• W2098751189 hasConcept C2778751355 @default.
• W2098751189 hasConcept C2778824825 @default.
• W2098751189 hasConcept C2778849439 @default.
• W2098751189 hasConcept C2779120738 @default.
• W2098751189 hasConcept C2779620165 @default.
• W2098751189 hasConcept C2780072125 @default.
• W2098751189 hasConcept C2780948078 @default.
• W2098751189 hasConcept C43554185 @default.
• W2098751189 hasConcept C62746215 @default.
• W2098751189 hasConcept C71924100 @default.
• W2098751189 hasConceptScore W2098751189C126322002 @default.
• W2098751189 hasConceptScore W2098751189C134018914 @default.
• W2098751189 hasConceptScore W2098751189C185592680 @default.
• W2098751189 hasConceptScore W2098751189C2776104379 @default.
• W2098751189 hasConceptScore W2098751189C2778163477 @default.
• W2098751189 hasConceptScore W2098751189C2778751355 @default.
• W2098751189 hasConceptScore W2098751189C2778824825 @default.
• W2098751189 hasConceptScore W2098751189C2778849439 @default.
• W2098751189 hasConceptScore W2098751189C2779120738 @default.
• W2098751189 hasConceptScore W2098751189C2779620165 @default.
• W2098751189 hasConceptScore W2098751189C2780072125 @default.
• W2098751189 hasConceptScore W2098751189C2780948078 @default.
• W2098751189 hasConceptScore W2098751189C43554185 @default.
• W2098751189 hasConceptScore W2098751189C62746215 @default.
• W2098751189 hasConceptScore W2098751189C71924100 @default.
• W2098751189 hasIssue "12" @default.
• W2098751189 hasLocation W20987511891 @default.
• W2098751189 hasLocation W20987511892 @default.
• W2098751189 hasLocation W20987511893 @default.
• W2098751189 hasLocation W20987511894 @default.
• W2098751189 hasOpenAccess W2098751189 @default.
• W2098751189 hasPrimaryLocation W20987511891 @default.

• next